Skip to main content

Table 2 Post-diagnostic exposure to aspirin and odds of breast cancer-specific death in breast cancer patients

From: Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink

Post-diagnostic aspirin exposure Breast cancer-specific deaths n (%) Controls n (%) Unadjusted OR (95% CI) P AdjustedaOR (95% CI) P Additionally adjustedbfor stage and grade OR (95% CI) P
No. prescriptions low dose       
  0 1,173 (81.7) 4,641 (81.5) 1.00   1.00   1.00  
  1 or more 262 (18.3) 1,056 (18.5) 0.98 (0.83, 1.15) 0.77 0.98 (0.81, 1.20) 0.86 1.00 (0.71, 1.41) 0.99
No. prescriptions low dose       
  0 1,173 (81.7) 4,641 (81.5) 1.00   1.00   1.00  
  1 to 11 117 (8.2) 525 (9.2) 0.88 (0.71, 1.09) 0.25 0.90 (0.71, 1.16) 0.42 0.80 (0.52, 1.24) 0.32
  12 or more 145 (10.1) 531 (9.3) 1.08 (0.87, 1.33) 0.48 1.08 (0.84, 1.39) 0.57 1.28 (0.82, 2.01) 0.27
No. tablets low dose       
  0 1,173 (81.7) 4,641 (81.5) 1.00   1.00   1.00  
  1 to 365 90 (6.3) 385 (6.8) 0.93 (0.72, 1.19) 0.55 1.01 (0.77, 1.33) 0.93 0.93 (0.57, 1.52) 0.78
  366 or more 172 (12.0) 671 (11.8) 1.01 (0.83, 1.22) 0.95 0.96 (0.76, 1.22) 0.76 1.05 (0.69, 1.58) 0.83
No. tablets low dose per day         
  0 1,173 4,641 (81.5) 1.00   1.00   1.00  
  0 to 0.5 93 (6.5) 370 (6.5) 0.99 (0.78, 1.27) 0.97 1.02 (0.78, 1.34) 0.89 0.89 (0.56, 1.42) 0.63
  >0.5 169 (11.8) 686 (12.0) 0.97 (0.80, 1.17) 0.72 0.96 (0.76, 1.21) 0.73 1.10 (0.72, 1.67) 0.67
No prescriptions high dose         
  0 1,415 (98.6) 5,642 (99.0) 1.00   1.00   1.00  
  1 or more 20 (1.4) 55 (1.0) 1.47 (0.87, 2.46) 0.15 1.15 (0.65, 2.04) 0.62 1.11 (0.31, 4.04) 0.87
  1. aModel includes chemotherapy within six months of diagnosis, radiotherapy within six months, tamoxifen (post diagnosis, during exposure period), aromatase inhibitors (post diagnosis, during exposure period), comorbidities (pre-diagnosis or during exposure period, including myocardial infarction, cerebrovascular disease, congestive heart disease, chronic pulmonary disease, peripheral vascular disease, peptic ulcer disease and diabetes), other medication exposure (post diagnosis, during exposure period, including statins, beta-blockers, ACE inhibitors, ARBs and metfomin) and smoking (pre-diagnosis, with missing included as a category).
  2. bAdjusted model additionally includes stage and grade, restricted to 574 cases and 2,268 controls with available data.